Clinical Trials Sponsored by Elevation Oncology

Total 4506 results

Elevation Oncology

Terminated

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)

Metastatic Breast Cancer

Germany, Spain, United States, Austria, Belgium, Canada
Elevation Oncology

Recruiting

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasm | Pancreas Neoplasm | Stomach Neoplasm

United States, Japan
Elevation Oncology

Active, not recruiting

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid Tumor

United States, Korea, Republic of, Australia, Canada
Elevation Oncology
Merrimack Pharmaceuticals

Terminated

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC (SHERLOC)

Adenocarcinoma | Non-Small Cell Lung Cancer | NSCLC | Heregulin

Spain, Canada, United States, Germany, Hungary, France
Levation Pharma, Ltd.

Completed

LEV102 Topical Gel in Acquired Blepharoptosis

Acquired Blepharoptosis

United States
Mural Oncology, Inc
Immune Oncology Network

Completed

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Non-cutaneous Squamous Cell Carcinoma of Head and Neck

United States
Hirschfeld Oncology

Not yet recruiting

Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer (GFLIPM)

Pancreatic Cancer

United States
Ikena Oncology

Recruiting

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Solid Tumor | Solid Tumors, Adult | Malignant Pleural Mesothelioma (MPM) | Epithelioid Hemangioendothelioma (EHE) | NF2 Deficient Mesothelioma | Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes | NF2 Deficiency | YAP1 or TAZ Gene Fusions

United States, United Kingdom
CivaTech Oncology

Recruiting

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Lung Cancer | Lung Cancer Stage I | Lung Cancer Stage II

United States
CivaTech Oncology

Recruiting

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Pancreatic Cancer

United States
Strata Oncology

Terminated

Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors (Sentinel)

Cancer

United States
Cardiff Oncology

Active, not recruiting

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Metastatic Colorectal Cancer | Colorectal Cancer

United States
CivaTech Oncology

Completed

Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source

Cancer | Pancreas Cancer

United States
CivaTech Oncology

Completed

Linear Source Registry for Prostate Cancer (CaRePC)

Prostate Cancer

United States
CureLab Oncology

Active, not recruiting

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer

Belarus
Que Oncology

Completed

Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen

Vasomotor Symptoms (VMS)
Bruckner Oncology

Completed

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Pancreatic Cancer

United States
Ikena Oncology

Recruiting

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Colorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene Mutation

United States
Cardiff Oncology

Completed

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Cardiff Oncology

Completed

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Surface Oncology

Completed

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Hematologic Cancers | Advanced Solid Cancers

United States, Canada
Radionetics Oncology

Recruiting

Phase 1 Study of 68Ga-R8760

Adrenocortical Carcinoma

United States
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
CivaTech Oncology

Not yet recruiting

CivaDerm(TM) Surface Therapy Pilot Study

Basal Cell Carcinoma | Squamous Cell Carcinoma of the Skin
Strata Oncology

Recruiting

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Lymphoma | Cancer | Adult Solid Tumor | Multiple Myeloma

United States
Cardiff Oncology

Completed

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Metastatic Colorectal Cancer | KRAS Gene Mutation

United States
Strata Oncology

Withdrawn

Strata EXPress™: A Study Using StrataEXP™ to Identify RNA-Expression Biomarkers in Advanced Cancer Patients (StrataEXPress)

Cancer

United States
Cardiff Oncology

No longer available

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | KRAS Gene Mutation
Cardiff Oncology

Active, not recruiting

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
Arch Oncology

Completed

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Alchemia Oncology

Unknown

Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC (FOLF(HA)iri)

Metastatic Colorectal Cancer

Australia
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology; Southwest Oncology Group

Completed

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Prostate Cancer

United States, Canada
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
Maastricht Radiation Oncology

Recruiting

The Effect of 360° Virtual Reality Movies on Fear and Anxiety (ENGAGE)

Breast Cancer | Head and Neck Cancer | Anxiety | Lung Cancer | Prostate Cancer | Brain Tumor | Fear

Netherlands
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Taiho Oncology, Inc.

Recruiting

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Pancreatic Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Cancer | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Siewert Type 1 GEJ Cancer

United States, Spain, Germany, France
Taiho Oncology, Inc.

Recruiting

A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351)

Non-Small Cell Lung Cancer

United States, France, Italy, Korea, Republic of, Japan, Spain, Germany, Netherlands, United Kingdom
ALX Oncology Inc.

Recruiting

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Bladder Cancer | Urothelial Carcinoma

United States
Children's Oncology Group

Not yet recruiting

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
RS Oncology LLC

Recruiting

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; Lung

United Kingdom
Maastricht Radiation Oncology

Recruiting

Lung Cancer Organoids and Patient Derived Tumor Xenografts (Lung organoids)

Lung Cancer

Netherlands
Kura Oncology, Inc.

Recruiting

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

HNSCC

United States
Taiho Oncology, Inc.

Recruiting

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Breast Cancer | Glioblastoma | Solid Tumor | Non-small Cell Lung Cancer

United States, France
Mural Oncology, Inc

Recruiting

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3)

Advanced Solid Tumor

United States, Spain
CG Oncology, Inc.

Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)

Non Muscle Invasive Bladder Cancer | High-grade Ta/ T1 Papillary Disease Bladder Cancer

United States, Korea, Republic of, Taiwan, Japan, Australia
Maastricht Radiation Oncology

Recruiting

Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial (IPON-1)

Carcinoma, Non-Small-Cell Lung

Netherlands
Celyad Oncology SA

Recruiting

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)

Unresectable Metastatic Colorectal Cancer

Belgium, United States
VM Oncology, LLC

Recruiting

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sarcoma | Cervical Cancer | Breast Cancer | Adenoid Cystic Carcinoma | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Thymic Carcinoma | Lung Cancer | Mesothelioma | Bladder Cancer | Head and Neck Carcinoma | Any Solid Tumors Progressed After a Prior Immunotherapy

United States, Puerto Rico
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Advanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)

United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
Kura Oncology, Inc.

Available

Expanded Access to Tipifarnib

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Clinical Trials Sponsored by Elevation Oncology

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations